Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04231864
Recruitment Status : Not yet recruiting
First Posted : January 18, 2020
Last Update Posted : January 18, 2020
Sponsor:
Collaborators:
AstraZeneca
Incyte Corporation
Information provided by (Responsible Party):
Alain Algazi, University of California, San Francisco

Brief Summary:
This phase II trial studies how well durvalumab and epacadostat work in treating patients with Epstein-Barr virus positive nasopharyngeal cancer that cannot be removed by surgery (unresectable), has come back (recurrent), or has spread to other places in the body (metastatic). Epacadostat blocks the enzyme, IDO1, from working. Blocking this enzyme may allow for a stronger immune response against cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving durvalumab and epacadostat may work better in treating patients with nasopharyngeal cancer compared to durvalumab alone.

Condition or disease Intervention/treatment Phase
Epstein-Barr Virus Positive Metastatic Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma Stage III Nasopharyngeal Carcinoma Stage IV Nasopharyngeal Carcinoma Stage IVA Nasopharyngeal Carcinoma Stage IVB Nasopharyngeal Carcinoma Biological: Durvalumab Drug: Epacadostat Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. Determine whether adding an IDO inhibitor to PD-L1 antibody therapy improves the probability of remission in nasopharyngeal carcinoma (NPC).

SECONDARY OBJECTIVES:

I. Determine whether adding an IDO inhibitor to PD-L1 antibody therapy improves long-term clinical outcomes in NPC.

II. Determine whether the combination of durvalumab and epacadostat in recurrent and metastatic NPC patients is safe and well tolerated.

EXPLORATORY OBJECTIVES:

I. Identify potential associations between pre-treatment and on-treatment regulatory and effector immune cell populations and clinical outcomes in NPC patients treated with durvalumab and epacadostat.

II. Characterize the oral and fecal microbiome in responding and non-responding patients.

OUTLINE:

Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.

After completion of study treatment, patients are followed up every 3 months until start of a new anti-cancer treatment, until 30 days after documented disease progression, until death, or until 36 months from the initiation of treatment on study, whichever comes first.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : April 1, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Treatment (durvalumab, epacadostat)
Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
Biological: Durvalumab
Given intravenously (IV)
Other Names:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
  • MEDI-4736
  • MEDI4736

Drug: Epacadostat
Given orally (PO)
Other Names:
  • INCB 024360
  • INCB024360




Primary Outcome Measures :
  1. Best overall response rate (BORR) [ Time Frame: Up to 2 years ]
    Patients will meet the primary endpoint (BORR) if they attain a confirmed complete response (CR) or partial response (PR) with the combination treatment with a 4-week confirmatory scan. All response data will be determined using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The point estimate and two-sided exact binomial 95% confidence interval for the objective response rate will be provided.


Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: up to 36 months ]
    Progression free survival (PFS) is defined as the number of days from enrollment to progression (for subjects who have progression) and the number of days from enrollment to last assessment (for subjects who do not have progression). The distributions of PFS will be summarized using the Kaplan-Meier method. Estimates of the median PFS will also be provided.

  2. Overall survival (OS) [ Time Frame: up to 36 months ]
    Overall survival (OS) defined as the number of days from enrollment to death, or from enrollment to date last known alive. The distributions of OS will be summarized using the Kaplan-Meier method. Estimates of the median OS will also be provided.

  3. Duration of response (DoR) [ Time Frame: up to 36 months ]
    Duration of response (DoR) is defined as the time (in days) from randomization to progression (or death from any cause) in patients who had a best overall response of complete response (CR) or partial response (PR). The distributions of DoR will be summarized using the Kaplan-Meier method. Estimates of the median DoR will also be provided.

  4. Biochemical Response to Treatment [ Time Frame: Up to 36 months ]
    Biochemical Response to Treatment will be obtained by measuring the metabolic response of the IDO1 enzyme (Trp/Kyn levels). Levels of tryptophan and kynurenine will be evaluated by liquid chromatography with tandem mass spectrometry to monitor systemic activity in modulating the IDO1 enzyme

  5. Biochemical Verification of Drug Efficacy [ Time Frame: Up to 36 months ]
    Biochemically verified drug efficacy will be obtained by measuring the metabolic response of the IDO1 enzyme (Trp/Kyn levels). Levels of tryptophan and kynurenine will be evaluated by liquid chromatography with tandem mass spectrometry to monitor systemic activity in modulating the IDO1 enzyme



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy of at least 4 months
  • Patient is capable of giving signed informed consent and is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Body weight > 40 kilograms (kg)
  • Patients must have a histological or cytological diagnosis of Epstein-Barr virus positive (EBV+) nasopharyngeal carcinoma that is not amenable to curative intent therapy (i.e. surgical resection, locoregional radiation therapy, concurrent chemoradiation)
  • Patients must decline, be ineligible or intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting, if such a therapy exists
  • Patients must have disease progression within 6 months of completion of platinum-based concurrent chemoradiation or after platinum-based chemotherapy administered for the treatment of recurrent or metastatic disease
  • If patient has known brain metastases, they must have stable neurologic status for at least 4 weeks without the use of steroids or on stable or decreasing dose of =< 10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs) (patients with a history of carcinomatous meningitis are not eligible)
  • Patients may have had prior chemotherapy or immunotherapy or radiation therapy. Patients should discontinue prior medical therapy at least 5 drug half-lives or 28 days prior to the first dose of treatment on study (whichever is shorter). Patients should complete any prior radiation therapy at least 14 days prior to the initiation of treatment on study. Also, any drug related adverse events identified during prior therapy must be well controlled (typically resolution to =< grade 1, OR resolved upon investigator review prior to initiation of this therapy
  • No systemic antineoplastic therapy may be received by the patient between the time of the biopsy and the first administration of study treatment
  • Patient must agree to any protocol mandated biopsies of tumor (deemed accessible, safe and appropriate for biopsy by the investigator?s assessment) and they must allow acquired tissue to be used for biomarker and immunological analysis
  • For women of childbearing potential, negative serum or urine pregnancy test within 14 days to the first epacadostat, or durvalumab and use of birth control from 30 days prior to the first administration of treatment on study and 120 days following last day administration of treatment on study
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
    • Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • Male patients must be surgically sterile, or must agree to use contraception during the study and at least 120 days following the last day of study drug administration

Exclusion Criteria:

  • Active autoimmune disease that has required systemic treatment in past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, rheumatoid arthritis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome or treated Graves disease) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  • Patients with celiac disease controlled by diet alone
  • Congestive heart failure (New York Heart Association class III to IV)
  • History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. Screening corrected QT (QTc) interval > 470 milliseconds is excluded. In the event that a single QTc is > 470 milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 470 milliseconds. For subjects with an intraventricular conduction delay (QRS interval > 120 milliseconds), the corrected JT (JTc) interval may be used in place of the QTc with sponsor approval. The JTc must be < 340 milliseconds if JTc is used in place of the QTc. Subjects with left bundle branch block are excluded
  • Uncontrolled or clinically significant conduction abnormalities (e.g., ventricular tachycardia on anti-arrhythmics are excluded), 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block (LAFB)/right bundle branch block (RBBB) are eligible
  • Uncontrolled, symptomatic ischemia within 6 months of first dose of study treatment or known myocardial infarction in the previous six months
  • Evidence of interstitial lung disease or any history of autoimmune pneumonitis including symptomatic and/or pneumonitis requiring treatment
  • Infectious
  • Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) requiring systemic therapy at time of study enrollment
  • Active hepatitis B (hepatitis B surface antigen [HBsAg] reactive) associated the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations > 1.5 x upper limit of normal (ULN). Patients who are HBsAg reactive must be on appropriate antiviral therapy while receiving treatment on study
  • Hepatitis C (hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
  • Presence of a gastrointestinal condition that may affect drug absorption. Administration of epacadostat through a feeding tube is permitted
  • Any other current or previous malignancy within the past 2 years that, in the opinion of the principal investigator will interfere with study-specific endpoints
  • Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
  • Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician
  • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician
  • History of leptomeningeal carcinomatosis
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice)
  • Hepatitis B ? Half of NPC patients have been infected with hepatitis B (Cancer Epidemol Biomarkers Prev. 2015. 24:1766-73, N = 711) and, therefore, inclusion of healthy patients with a history of hepatitis B is a central part of this study. In addition, PD-1 antibodies have been proven to be safe in patients with active hepatitis and hepatocellular carcinoma (e. g. KEYNOTE 224). However, patients with hepatitis B virus (HBV) surface antigen positive (HBSAg) must have AST and total bilirubin < 1.5 x ULN AND
  • Negative HBV RNA polymerase chain reaction (PCR) OR
  • On antivirals for HBV AND at least 8 weeks of prior anti-PD1 antibody therapy AND no history of AST or total bilirubin levels > 1.5 x ULN due to PD-1 antibody therapy
  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Known human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) ? Consistent with current guidelines from the NCI / Cancer Therapy Evaluation Program (CTEP), ?HIV infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial? (CTEP protocol template)
  • Intercurrent illness not otherwise specified
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • Patients receiving systemic steroid therapy for a chronic inflammatory condition. Topical steroids, nasal and inhaled steroids are permitted. Prednisone or equivalent =< 10 mg/day is permitted as hormone replacement; higher dosage prednisone should be stopped at least 14 days prior to cycle 1 day 1 (c1d1)
  • Subjects receiving monoamine oxidase inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before screening
  • Any history of serotonin syndrome (SS) after receiving serotonergic drugs
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
  • Receipt of live attenuated vaccine within 30 days before the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
  • Current or prior use of immunosuppressive medication within 14 days (use 28 days if combining durvalumab with a novel agent) before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
  • Absolute neutrophil count (ANC) < 1.0 x 10^9/L
  • Platelets < 75 x 10^9/L
  • Hemoglobin < 9 g/dL or < 5.6 mmol/L (transfusion is acceptable to meet this criterion)
  • Serum creatinine >= 1.5 x institutional upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or creatinine clearance (CrCl)) < 50 mg/min for subjects with creatinine levels > 1.5 x institutional ULN
  • AST or ALT > 2.5 x institutional ULN
  • Alkaline phosphatase > 2.5 x ULN

    • Note: Subjects with 1) bone metastases and gamma-glutamyl transpeptidase (GGT) < 2.5 x ULN may enroll if the alkaline phosphatase is < 5 x ULN
  • Total bilirubin above 1.5 x the institutional ULN AND conjugated bilirubin >= 2.0 x ULN
  • International normalized ratio (INR) or prothrombin time (PT) > 1.5 x ULN
  • Activated partial thromboplastin time (aPTT) > 1.5 x ULN

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04231864


Contacts
Layout table for location contacts
Contact: Carter Hultman (415) 502-4707 carter.hultman@ucsf.edu
Contact: Alain P Algazi, MD 877-827-3222 cancertrials@ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94115
Contact: Carter Hultman    415-502-4707    carter.hultman@ucsf.edu   
Contact: Alain P Algazi, MD    877-827-3222    cancertrials@ucsf.edu   
Principal Investigator: Alain P. Algazi         
Sponsors and Collaborators
Alain Algazi
AstraZeneca
Incyte Corporation
Investigators
Layout table for investigator information
Principal Investigator: Alain P Algazi, MD University of California, San Francisco

Layout table for additonal information
Responsible Party: Alain Algazi, Associate Professor, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04231864    
Other Study ID Numbers: 18209
NCI-2019-06736 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: January 18, 2020    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Nasopharyngeal Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Durvalumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs